Stocks and Investing Stocks and Investing
Tue, April 19, 2022

Vamil Divan Maintained (ACAD) at Hold with Decreased Target to $27 on, Apr 19th, 2022


Published on 2024-10-27 20:30:23 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $28 to $27 on, Apr 19th, 2022.

Vamil has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 3 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Decreased Target to $24 on, Monday, March 7th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021


These are the ratings of the 6 analyists that currently disagree with Vamil


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $31 on, Wednesday, March 16th, 2022
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $37 on, Thursday, March 10th, 2022
  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
Contributing Sources